The vaccine candidate comprises five recombinant antigens corresponding to highly conserved merozoite surface proteins (including sub-regions) of two major parasite species that infect humans. Inducing satisfactory immune responses being one of the objectives, positive results have been reached during extensive efficacy testing in primates.